---
title: "MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286468852.md"
description: "MAIA Biotechnology has decided to terminate its at-the-market (ATM) sales agreement with H.C. Wainwright, effective seven business days after May 14, 2026. This decision ends the agreement made on February 14, 2024, under which the company raised approximately $5.68 million by selling 3,116,012 shares. The termination aligns with MAIA's capital markets strategy, and no termination fees were disclosed."
datetime: "2026-05-14T21:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286468852.md)
  - [en](https://longbridge.com/en/news/286468852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286468852.md)
---

# MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M

MAIA Biotechnology suspended sales under its at-the-market (ATM) program and notified H.C. Wainwright of its decision to terminate the sales agreement, effective seven business days after May 14, 2026. The move ends the February 14, 2024 agreement under which the company sold 3,116,012 shares for gross proceeds of about $5.68 million since a March 28, 2025 prospectus supplement for up to $11.2 million. The company did not disclose any termination fees and indicated the step aligns with its capital markets strategy.

**Agreement details:**

-   **Agreement terminated**: At The Market Offering Agreement for common stock sales
-   **Counterparty**: H.C. Wainwright & Co.
-   **Original agreement date**: Feb 14 2024
-   **Termination date**: May 26 2026
-   **Termination type**: Early
-   **Reason**: Adjust capital-raising strategy

Original SEC Filing: MAIA Biotechnology, Inc. \[ MAIA \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MAIA.US](https://longbridge.com/en/quote/MAIA.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)